Business · 19/05/1994Updated: 10/16/2026 · 1 min read
FDA Proposes to Disapprove New Drug Application for Deprenyl Gelatin Capsules and Liquid
Summary
The US Food and Drug Administration (FDA) proposes to disapprove a new drug application for Deprenyl Gelatin Capsules and Liquid submitted by Discovery Experimental and Development, Inc., citing insufficient information on the safety and efficacy of the treatment for Alzheimer's disease.
Original source language: Federal Register — Health and Human ServicesOpen original release →